Blue Cross Blue Shield - Iowa Biomarker Coverage

Not covered — investigational

Covered when ALL of the following are met:

Investigational biomarkers: Measurement of nontraditional lipid and non-lipid biomarkers (including apolipoprotein B, apolipoprotein AI, apolipoprotein E, LDL subclass, HDL subclass, lipoprotein[a], B-type natriuretic peptide, cystatin C, fibrinogen, leptin) as an adjunct to LDL cholesterol for cardiovascular risk assessment and management is considered investigational and not covered.

Evidence insufficient to demonstrate improved net health outcome.

Lp-PLA2: Measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) for risk assessment or management of cardiovascular disease is considered investigational and not covered.

Evidence insufficient to demonstrate improved net health outcome.

CVD risk panels: Cardiovascular disease risk panels that report multiple individual novel biomarkers or other laboratory studies (beyond a simple lipid panel) for the purpose of cardiac risk assessment are considered investigational and not covered.

Evidence insufficient to demonstrate improved net health outcome.

Evidence synthesis / coverage-relevant findings

Evidence-based conclusions regarding apolipoprotein testing:

Apo B predictive evidence: Apolipoprotein B (apo B) is an independent predictor of cardiovascular events in multiple large prospective cohorts and RCT secondary analyses, and in some studies outperforms LDL-C for risk prediction; however, pooled meta-analyses and reclassification analyses generally show little or no improvement in overall risk prediction when apo B substitutes for traditional lipid measures and may slightly worsen discrimination metrics in some analyses.

Supported by systematic reviews and ERFC pooled analyses.

Apo AI and apo B/apo AI ratio evidence: Apolipoprotein AI and the apo B/apo AI ratio are predictive of cardiovascular risk and in many studies perform similarly to traditional lipid measures; any incremental improvement over LDL/HDL measures is small and of uncertain clinical significance.

Supported by cohort studies and meta-analyses.

Clinical model inclusion: Although apo measures have been included in some statistical risk models, they are not incorporated into most routine clinical risk models (e.g., Framingham), and evidence does not establish that use of apo measures to guide management improves patient outcomes.

Apolipoprotein AI

Summary interpretation of evidence for apolipoprotein AI and apo B/apo AI ratio

Apo AI and apo B/apo AI ratio: Measurement of apolipoprotein AI and the apo B/apo AI ratio predicts cardiovascular risk similarly to traditional lipid measures; any incremental predictive gain is small and of uncertain clinical significance, and tools to translate these results into management decisions that improve outcomes are lacking.

Evidence from cohort studies, RCT subgroup analyses, and meta-analyses.

APOE genotyping

Summary interpretation of evidence for APOE genotyping

APOE genotype is associated with lipid levels and coronary artery disease risk to some degree but provides little additional clinically actionable information beyond established risk factors; it is not part of standard cardiac risk models and evidence does not show that APOE genotyping improves clinical outcomes.

Not identified as an important emerging risk factor in ATP III.

NMR-measured HDL/LDL particles

Summary interpretation of evidence for HDL and LDL particle measures (NMR)

HDL particle number/size: NMR-measured HDL particle concentration is associated with cardiovascular disease in some analyses, but uncertainty exists about how these measurements should change management beyond traditional lipid measures.

Heterogeneous evidence; clinical utility unproven.

LDL particle size/number: LDL particle number and size measured by NMR are associated with cardiac risk in cohort studies, but available data do not demonstrate superior predictive ability compared with traditional lipid measures nor that use of NMR particle measures to guide therapy improves health outcomes.

Proposed LDL particle concentration targets exist but outcome benefit when targeting these values has not been demonstrated.

Lipoprotein(a)

Summary interpretation of evidence for lipoprotein(a)

Lipoprotein(a) (Lp[a]) is an independent risk factor for cardiovascular disease across multiple cohort studies and meta-analyses; adding Lp(a) to traditional risk factors yields only small incremental improvements in prediction, and there is insufficient evidence that routine measurement and use of Lp(a) levels improves clinical outcomes.

High Lp(a) (eg, >90th–95th percentile) associated with higher event rates; clinical utility for treatment decisions remains uncertain.

Coverage criteria — nontraditional cardiac biomarkers

Coverage considerations for nontraditional biomarkers in asymptomatic individuals or patients on lipid-lowering therapy

General evidence requirement: Testing for nontraditional cardiac biomarkers should be supported by evidence that test results will change clinical management in ways that improve net health outcomes; for many markers (eg, cystatin C, fibrinogen, leptin) such evidence is not identified.

Based on systematic reviews and cohort studies showing association but no outcome benefit.

Apolipoprotein testing: Apo B and apo AI have shown incremental predictive value in some analyses and on-treatment levels correlate with residual risk, but it is not established that measuring these biomarkers and acting on results improves outcomes compared with standard lipid-guided care.

Evidence from RCT secondary analyses and patient-level meta-analyses.

Use of surrogates before expanded testing: Non–HDL-C and LDL-C on treatment correlate with apo B and may serve as adequate surrogates during statin therapy; optimize conventional lipid targets before considering apolipoprotein or particle testing.

General medical necessity logic for nontraditional lipid/cardiac biomarker tests

Evidence requirements: For a nontraditional biomarker or panel to be considered medically necessary, there must be demonstration of (1) clinical validity (independent prediction of risk beyond standard factors) AND (2) clinical utility — direct evidence (preferably randomized trials or validated decision models) that using the test to guide management improves patient health outcomes.both conditions required

Derived from policy requirement for linked clinical validity and demonstrated outcome benefit.

Overall coverage considerations

Summary of evidence-based stance

Lp-PLA2 evidence summary: Lp-PLA2 level is an independent predictor of coronary artery disease in multiple meta-analyses, but there is insufficient evidence that adding Lp-PLA2 to existing models yields clinically meaningful reclassification or that Lp-PLA2 testing alters management to improve outcomes.

No randomized trials demonstrating clinical utility; decision modeling may be required to support use.

Coverage stance for individual biomarkers and panels

Covered only when evidence demonstrates clinical utility leading to improved net health outcome

Required evidentiary conditions: (1) High-quality evidence (preferably randomized controlled trials or strong prospective intervention studies) showing that use of the specific biomarker or panel to guide management results in improved patient outcomes; (2) External validation demonstrating incremental and clinically meaningful improvement in risk prediction and decision-making compared with established risk tools.clinical utility demonstrated

Evidence currently lacking for most individual biomarkers and panels; small improvements in discrimination have not translated into outcome benefit.

General coverage requirement for CVD risk panels and novel biomarkers

Coverage contingent on demonstration of clinical validity and impact on management:

Primary requirement: There must be evidence that the specific test or panel has clinical validity (accurately and independently identifies risk) and that use of the result changes management in ways that improve net health outcomes; preference is for randomized or high-quality interventional evidence or robust validated decision models showing outcome benefit.evidence of clinical validity and demonstrated change in management leading to improved outcomes

Indirect evidence alone is insufficient to establish coverage.

Selective coverage for specific biomarkers per guideline indications

Selective measurement may be reasonable when guideline-specified criteria are met:

Guideline-supported indications: Measurement of specific biomarkers (for example, Lp(a) or apo B) may be reasonable and considered in selected populations per specialty society guidance — e.g., family history of premature ASCVD, markedly elevated inherited Lp(a), triglycerides ≥200 mg/dL, intermediate/borderline estimated ASCVD risk when additional risk-enhancing information may change treatment decisions, or to refine risk when standard assessment is uncertain.meets guideline-specified condition

Specific thresholds and indications vary by guideline (ACC/AHA, ESC/EAS, AACE, NLA).

This policy is not intended to address use of biomarker panels for diagnosing acute myocardial infarction. The policy guidelines explicitly state that panels of biomarkers used for AMI diagnosis are outside the scope of this document.

Lipoprotein-associated phospholipase A2 (Lp-PLA2) assays have been investigated as a biomarker for coronary artery disease; however, clinical trials of Lp-PLA2 inhibitors did not show significant reductions in CAD endpoints, and Lp-PLA2 measurement was not used to select or manage subjects in those trials. Consequently, routine Lp-PLA2 testing to guide management lacks supporting trial evidence.

No explicit exclusions are listed in the cited subsection beyond the general investigational stance for nontraditional biomarkers; the summary of evidence focuses on limitations of clinical utility rather than identifying additional formal exclusions.

Nuclear magnetic resonance (NMR) measures of LDL particle size and number have been associated with cardiovascular risk in some studies, but evidence does not demonstrate that using NMR particle measures to guide therapy improves health outcomes. Therefore, NMR particle testing for the sole purpose of directing treatment decisions is not supported by outcome data.

Meta-analyses and cohort studies report associations between B-type natriuretic peptide (BNP) or cystatin C levels and cardiovascular risk, but no studies were identified showing that use of BNP or cystatin C testing in clinical care leads to improved patient outcomes. As a result, routine testing of these markers for asymptomatic risk assessment lacks demonstrated clinical benefit.

Although cystatin C, fibrinogen, and leptin have been associated with cardiovascular risk in observational studies and meta-analyses, the evidence does not show that measuring these markers to guide clinical care improves outcomes. Testing with the intention of altering management to improve net health outcome is therefore unsupported by current evidence and may be considered not medically necessary.

Replacing conventional LDL-C/HDL-C targets with alternative measures such as apo B, apo AI, APOE genotype, LDL particle size/subclass, Lp(a), or Lp-PLA2 as routine practice is not supported by evidence showing improved outcomes. The policy notes that while some markers provide incremental predictive information, there is no direct evidence that substituting these measures for standard lipid targets leads to better patient health outcomes.

No randomized controlled trials were identified demonstrating that management guided by Lp-PLA2 testing improves health outcomes. The absence of direct intervention evidence means that strategies relying on Lp-PLA2 to change patient management lack established clinical utility.

Tests and commercially available cardiovascular disease risk panels that have not demonstrated an impact on clinical management or patient health outcomes are excluded from coverage as clinically useful interventions. The policy emphasizes that panels without established clinical validity and demonstrated management impact are not supported for routine use.

Panels combining multiple novel risk markers frequently lack standardized composition and validated methods for integrating results. Because their clinical validity and impact on management have not been established, such multi-marker panels are not supported for routine clinical use and may be excluded from coverage.

This portion of the document does not provide explicit coverage criteria or medical necessity statements; it primarily contains coding guidance and reference material rather than new coverage rules.

The listed nontraditional biomarkers and CVD risk panels are considered investigational when used as adjuncts to LDL cholesterol for risk assessment and management because current evidence does not demonstrate that testing these markers changes management in ways that improve net health outcomes.

Although apolipoprotein measures (apo B and apo AI) have been associated with cardiovascular risk in large cohort studies, pooled analyses and meta-analyses have not shown consistent improvement in overall risk prediction when substituting these measures for traditional lipids; some analyses reported a slight worsening in discrimination metrics.

Routine measurement of LDL particle size or concentration by NMR solely to adjust therapy is not supported by current evidence. The policy states that while LDL particle measures correlate with risk and may reflect residual risk on treatment, there is no evidence that acting on these measurements improves clinical outcomes.

BNP and cystatin C are associated with cardiovascular risk in observational data, but testing these markers for risk assessment in asymptomatic populations lacks evidence of improved outcomes and therefore is not supported as a routine strategy.

Testing for cystatin C, fibrinogen, or leptin to assess cardiovascular risk in asymptomatic individuals is not supported by evidence demonstrating improved health outcomes. The policy highlights that associations with risk do not establish that clinical use of these tests leads to better patient care.

Use of apo B, apo AI, the apo B/apo AI ratio, APOE genotype, LDL particle size/subclass, Lp(a), or Lp-PLA2 as routine replacements for conventional lipid measures in clinical care has not been shown to improve outcomes. The policy indicates these tests should not replace standard lipid assessment for routine risk stratification or therapy decisions absent evidence of clinical benefit.

Because no direct intervention studies (randomized controlled trials) demonstrate that Lp-PLA2–guided management improves patient outcomes, testing strategies premised on clinical utility of Lp-PLA2 are not established and would require high-quality trials or robust decision models to justify routine use.

Individual novel biomarkers or multi-marker panels are considered not medically necessary for routine cardiovascular risk stratification when the evidence shows only small improvements in prediction metrics without demonstrated changes in management or outcome benefit. The policy requires demonstration of clinically meaningful utility before routine coverage.

Routine use of commercially available cardiovascular disease multi-marker panels is considered not medically necessary because clinical validity has not been established and there is no evidence that panels improve clinical management or patient outcomes.

No additional specification is provided in this section of the policy regarding other exclusions or procedural changes; the coding section reiterates that appropriate CPT/HCPCS and diagnosis codes should be used when reporting services.

Provider Actions — Authorization, Documentation, and Billing

Prior Authorization

Prior Approval / Benefit Verification

Prior Approval: Not applicable for this policy as stated in the policy header; however, benefit verification and applicable state law should be confirmed prior to ordering tests.

Verify member benefits and any applicable state-mandated coverage (e.g., Iowa House File 2668) before ordering biomarker testing.
Prior approval: Not required per policy header, but coverage may vary by contract — confirm eligibility.

Prior Authorization

Prior Authorization — Apolipoproteins and Therapy Guidance

Prior authorization is specifically recommended/considered for certain apolipoprotein tests when results are intended to guide therapy, and where clinical utility has not been validated.

Prior authorization for apo B / apo AI testing may be required when results will be used to guide treatment decisions.
When testing is used to guide therapy, require documentation demonstrating validated clinical utility or a rationale for how results will change management to improve net health outcome.

Prior Authorization

Prior Authorization — Validated Clinical Utility Required

Require validated clinical utility when prior authorization is sought for nontraditional lipid or non-lipid biomarker testing; if clinical utility is unproven, prior authorization is recommended and testing may be denied.

Tests considered investigational (e.g., many nontraditional lipid and non-lipid biomarkers, Lp-PLA2, and cardiovascular risk panels) lack sufficient evidence of improved net health outcome and generally require demonstration of validated clinical utility for authorization.
If clinical utility is unproven, prior authorization is recommended and lack of demonstrated clinical utility may lead to denial.

Note

Authorization / Coverage Directives — Not Explicit

No explicit authorization or coverage directives for many specific tests are provided in the policy; the document primarily summarizes evidence and investigational status.

Regulatory status is described (FDA 510(k) clearances and CLIA lab-developed tests) but does not itself indicate coverage.
The policy does not provide prescriptive authorization criteria for many individual biomarkers; absence of coverage directive means benefit verification and medical necessity review are needed.

Note

NMR LDL Particle Testing — Evidence Summary

NMR LDL particle testing: evidence shows association with cardiovascular risk but does not demonstrate improved health outcomes when used beyond traditional lipid measures.

NMR-measured LDL particle number/size is associated with cardiac risk and proposed target values exist, but studies have not shown added predictive ability beyond traditional lipid measures nor improved patient outcomes.
Proposed LDL particle concentration targets (Framingham percentiles): 20th = 1100 nmol/L, 50th = 1400 nmol/L, 80th = 1800 nmol/L (informational only).

Documentation Required

Documentation Requirements and Study Expectations

Documentation expectations: when requesting nontraditional biomarker testing, documentation should support how the test result would change management to improve net health outcome; otherwise testing may be considered investigational.

Document the specific clinical question and how results will alter treatment decisions or monitoring.
If using commercial multi-analyte panels, document the specific analytes requested and the rationale for each.
Studies/documentation should demonstrate direct evidence of clinical utility (preferably RCTs) or a plausible chain of evidence linking test performance to management changes and improved outcomes.

Step Therapy

Step Therapy / Testing Sequence

Step therapy / testing sequence: use conventional risk assessment and standard lipid measures (e.g., LDL-C, non-HDL-C, HDL, triglycerides) as the first-line approach before ordering nontraditional biomarkers or panels.

Use surrogate lipid measures (e.g., non-HDL-C) as an adequate surrogate for apo B in many contexts, particularly during statin therapy.
Standard-of-care interventions (diet, statins) remain primary treatment steps; nontraditional testing should not replace conventional assessment.
Step therapy approach: perform conventional risk assessment and standard lipid panel first; consider nontraditional testing only if results would meaningfully change management and clinical utility is documented.

Denial Risk

Denial Risk — Investigational Tests and Panels

Investigational status and denial risk: many biomarkers and risk panels are considered investigational because no studies have demonstrated improved health outcomes; lack of demonstrated clinical utility may trigger denial.

Tests deemed investigational include many apolipoprotein uses, Lp-PLA2, cystatin C, fibrinogen, leptin, and commercial CVD risk panels.
Because no high-quality studies show that use of these markers changes management to improve outcomes, requests may be denied as not medically necessary.

Billing Rule

Billing and Coding

Coding and billing: use appropriate laboratory CPT/HCPCS/ICD codes when reporting services; ensure codes reflect the specific analytes performed.

Report the specific laboratory CPT and HCPCS codes corresponding to the tests ordered.
When ordering multi-analyte commercial panels, document the individual analytes so billing matches services provided.

Note

References / Evidence Base

References: This section contains bibliographic citations and evidence summaries supporting the policy conclusions and recommendations.

Refer to the policy's References section for the cited literature and supporting studies.

Definitions and Key Terms

Simple lipid panel

ComponentsTotal cholesterol; LDL‑C; HDL‑C; triglycerides

Calculated ratiosMay include total/HDL ratio or other calculated lipid ratios

Not included testsApolipoproteins, particle number/size, and Lp(a) are not components of a simple lipid panel per policy guidelines

Cardiovascular risk panel

DefinitionCommercially available combinations of multiple biomarkers (lipids, inflammatory markers, metabolic parameters, genetic markers, radiologic markers) reported together to assess CVD risk

Panel variabilityPanel contents vary widely between vendors (some include CAC, carotid IMT, genetic markers, etc.)

DistinctionPanels report individual analytes rather than producing a single integrated risk score (distinct from quantitative risk calculators)

Apolipoprotein B (apo B)

Biologic roleApo B is the major apolipoprotein of atherogenic lipoproteins and reflects total LDL/VLDL particle number

Clinical interpretationProposed as a better measure of atherogenic potential than LDL‑C because particle number can vary for a given LDL‑C

On‑treatment relevanceOn‑treatment apo B correlates with residual risk in some RCT analyses but replacement of standard targets is not established

Apolipoprotein AI (apo AI)

Biologic roleApo AI is the principal apolipoprotein of HDL and approximates HDL particle number

Ratio useThe apo B/apo AI ratio has been proposed as a measure of pro‑ versus anti‑atherogenic particle balance

Clinical statusApo AI and apo B/apo AI perform similarly to traditional lipids for risk prediction; tools to translate measurements into management are lacking

HDL/LDL particle subclass

DefinitionSubclassification of HDL and LDL by particle size/density (e.g., HDL2 vs HDL3; LDL pattern A vs B) with clinical interest in small, dense LDL being more atherogenic

Measurement methodsMeasured by NMR spectroscopy, gradient‑gel electrophoresis, or other fractionation techniques

Therapeutic implicationsSome therapies preferentially affect particle size/number but evidence that targeting subclasses improves outcomes is lacking

Lipoprotein(a) (Lp[a])

StructureLp(a) is an LDL‑like particle with an additional apo(a) covalently linked to apo B; levels are largely genetically determined

Risk associationLp(a) is an independent risk factor for CVD across cohorts and meta‑analyses but adds only small incremental predictive value

High‑risk thresholdEvent rates notably higher at ≥90th percentile

Lp-PLA2

Marker descriptionLp‑PLA2 is an enzyme associated with LDL thought to have a proinflammatory role in atherosclerosis

Trial evidenceClinical trials of Lp‑PLA2 inhibitors did not show significant reductions in CAD endpoints; testing was not used to select/manage trial subjects

Evaluation criteriaATP‑III criteria recommend assessing independent predictive power, prevalence, assay standardization, and evidence that modification reduces risk

Clinically Valid / Clinical utility

Clinical validity requirementA test must detect presence/absence of a condition, risk of developing a condition, or treatment response to be considered clinically valid

Clinical utility definitionA test is clinically useful if its results inform management decisions that improve net health outcomes (preferably shown in RCTs)

Evidence hierarchyDirect evidence of utility comes from intervention studies comparing outcomes with and without the test; indirect evidence rests on clinical validity

apo B/apo AI ratio

Ratio definitionApo B/apo AI ratio reflects balance of proatherogenic (apo B) to anti‑atherogenic (apo AI) particles

Predictive findingsThe ratio has been predictive of events in some trials and pooled analyses but is not consistently superior to conventional lipid ratios

Use in practiceAlthough prognostic, substitution for standard lipid measures has not been shown to improve clinical outcomes

APOE genotype

DefinitionAPOE genotype denotes genetic variants (e2, e3, e4) associated with differing lipid levels and variable response to diet/statins

Clinical impactAPOE genotype is associated with lipid levels and may predict differential response to therapy, but evidence that genotyping improves outcomes is lacking

GuidanceAPOE testing is not part of standard cardiac risk models and currently provides little actionable management guidance

LDL particle concentration (nmol/L)

Units reportedLDL particle concentration reported in nmol/L when measured (commonly by NMR)

Target percentilesProposed targets correspond to 1100, 1400, 1800 nmol/L for 20th, 50th, and 80th percentiles respectively

Method mappingCPT/HCPCS mappings reference NMR particle quantitation codes (e.g., 83704 mapping shown)

Lipoprotein(a) [Lp(a)]

Definition and riskLp(a) is an LDL‑like particle with apo(a); genetically determined levels are independently associated with CVD risk

Measurement contextUsed as an incremental risk marker in cohort studies and meta‑analyses; standardization and clinical action thresholds vary

High‑risk percentileEvent rates most pronounced at ≥90th percentile

Lp(a)

Evidence summaryMultiple cohort studies and meta‑analyses show Lp(a) as an independent predictor of CVD though magnitude is modest

Clinical utility uncertaintyAddition to traditional risk models yields only small predictive gains and practical management implications are unclear

Prevalence noteApproximately 20% of patients with CAD have elevated Lp(a) levels

BNP / NT-proBNP

BNP/NT‑proBNP associationElevated BNP/NT‑proBNP levels are associated with higher risk of cardiovascular events and heart failure

Example cutpointsBNP >80th percentile examples: 20.0 pg/mL (men), 23.3 pg/mL (women) linked to increased hazard for death and events

Outcome dataNo evidence identified that routine BNP testing in asymptomatic populations improves clinical outcomes

Cystatin C

Marker roleCystatin C is a renal function marker associated with higher CVD risk and mortality in meta‑analyses

Predictive performanceHigher cystatin C associated with greater risk (pooled aHR for cardiovascular mortality ~2.74 comparing highest vs lowest categories)

Clinical utilityAdding cystatin C to risk models did not consistently improve prediction; no evidence that testing improves outcomes

Fibrinogen

Association with riskFibrinogen is associated with higher CVD and all‑cause mortality and improves predictive accuracy modestly

MagnitudeMeta‑analyses report ~30–34% higher CVD or mortality risk per higher fibrinogen categories

Clinical importanceDespite improved predictive accuracy, addition to established risk factors was not shown to be clinically important

Clinical utility

Definition of clinical utilityA test is clinically useful if its results inform management decisions that improve net health outcomes (correct/ more effective therapy, avoid unnecessary therapy/testing)

Preferred evidenceDirect evidence from randomized controlled trials comparing outcomes with and without use of the test

Indirect chain of evidenceClinical utility may be inferred indirectly if clinical validity is strong and linked to effective management changes

apo B

Apo B as predictorOn‑treatment apo B has been a significant predictor of cardiovascular events in several RCT analyses

Comparative performanceSome trials found apo B predicted events when LDL did not (e.g., TNT combined analyses HR ~1.24), but overall incremental predictive gains over traditional lipids are small

Practical implicationEvidence does not establish that routine apo B measurement to guide therapy improves outcomes

apo AI / apo B/apo AI ratio

Apo AI / ratio evidenceApo AI and the apo B/apo AI ratio predict cardiovascular events in many cohorts and some RCT analyses

Relative performanceThese measures are generally as good as traditional lipid measures but offer only small and inconsistent incremental benefit

Clinical translationTools to translate apo AI or ratio results into management decisions are not established

APOE genotype

APOE polymorphism impactAPOE alleles (e2, e3, e4) associate with differing lipid levels and may influence response to diet or statins

Outcome relevanceAlthough genotype correlates with lipid response, evidence that APOE genotyping improves clinical outcomes or alters management is lacking

Clinical useAPOE testing is not part of routine cardiac risk models and has limited actionable guidance

LDL particle size/subclass

LDL particle size/subclass definitionDistinguishes small, dense LDL (pattern B) from larger LDL (pattern A); small dense LDL considered more atherogenic

Measurement methodsMeasured by NMR, gradient‑gel electrophoresis, ultracentrifugation or other fractionation techniques

Outcome evidencePreferential changes in particle size with some therapies observed but no clear evidence that targeting size/subclass improves clinical outcomes

Lp-PLA2

Association with eventsLp‑PLA2 activity/levels are independent predictors of CAD in multiple meta‑analyses and cohort studies

Clinical trialsIntervention trials of Lp‑PLA2 inhibitors did not reduce CAD endpoints and testing was not used to select/ manage trial subjects

Utility conclusionNo direct evidence that Lp‑PLA2 testing changes management to improve outcomes

Lp-PLA2 testing

Testing descriptionMeasurement of Lp‑PLA2 levels as a biomarker for CAD risk

Regulatory/assay noteAssays exist but trials of Lp‑PLA2 inhibitors failed to show benefit; testing has not informed trial selection

Coverage implicationLack of outcome‑proven utility supports investigational stance for routine use

CVD risk panels

Panel definitionCVD risk panels are multi‑biomarker panels assessing inflammatory, lipid, metabolic, genetic, and sometimes radiologic markers to stratify CVD risk

HeterogeneityPanel composition varies widely; results from single‑marker studies cannot be generalized to panels

Evidence gapNo published studies evaluating commercially available CVD risk panels' impact on clinical care were identified

Multimarker panel

Multimarker panel examplede Lemos et al evaluated a 5‑marker panel (CAC >10, NT‑proBNP ≥100 pg/mL, hs‑troponin ≥5 ng/L, hs‑CRP ≥3 mg/L, LVH on ECG) showing improved C statistic in cohorts but uncertain clinical utility

PerformanceMESA C‑statistic increased from 0.73 to 0.786 when incorporating individual test results (p<.001) but translation to management remains unclear

ReclassificationCategory‑free NRI reported but clinical actionability not established

Clinically useful test

Clinically useful test criteriaA test is clinically useful if results inform management decisions that improve net health outcome; ideally supported by RCTs showing outcome benefit

Documentation expectationEvidence should show how test results change management in ways known to improve outcomes

Policy implicationTests/panels without demonstrated impact on management or outcomes are considered investigational and not covered routinely

apo B

apo B measurement roleMeasures atherogenic particle number; on‑treatment apo B correlates with residual risk in several studies

Predictive comparisonsApo B has in some analyses outperformed LDL‑C for predicting events, but overall incremental benefit for management is unproven

Surrogate useNon‑HDL‑C may serve as an adequate surrogate for apo B during statin therapy

apo AI / apo B/apo AI ratio

Apo AI evidenceApo AI and the apo B/apo AI ratio are predictive of cardiovascular risk in many studies

Comparative utilityThese measures are generally as good as traditional lipids; small incremental improvements are of uncertain clinical importance

Guideline incorporationApo AI and ratios are not incorporated into routine risk models (e.g., ATP III) for clinical decision making

APOE genotype

APOE genotype summaryAPOE genotype correlates with lipid levels and may influence treatment response, but current evidence does not support routine use to change management

Predictive variabilityE2 associated with lower cholesterol, e4 with higher; response to diet/statins may vary by allele

Outcome evidenceNo adequate evidence that APOE genotyping improves patient outcomes when used clinically

LDL particle size / LDL particle concentration

LDL particle size / concentrationSmall, dense LDL (pattern B) considered more atherogenic; particle number/size measured by NMR associated with risk but clinical utility unproven

Measurement optionsNMR particle number, gradient‑gel electrophoresis, ultracentrifugation available; CPT/HCPCS codes map to these tests

Therapy implicationsSome therapies alter particle size/number but no RCT evidence shows targeting these measures improves outcomes

APOE polymorphism

APOE polymorphism implicationsAPOE polymorphisms associate with lipid levels, coronary risk, and variability in response to statins; may predict treatment response in some studies

Clinical translationDespite associations, APOE testing lacks clear guidance to alter standard treatment approaches

Evidence statusNo demonstration that APOE testing improves outcomes when used to guide therapy

Liposcale / NMR lipoprotein profile

Liposcale / NMR profileAdvanced NMR lipoprotein profile (e.g., Liposcale) provides quantitation of particle numbers and subclasses and is HCPCS/CPT mapped

Report featuresProfiles can include 20+ variables including particle concentrations for HDL, LDL, VLDL and subclass distributions

CodingProprietary NMR panels have HCPCS mappings (e.g., 0541U) and CPT mappings for particle quantitation (e.g., 83704)

Ceramides test

Ceramides test descriptionLC‑MS/MS plasma ceramide quantitation with an associated risk score for major cardiovascular events (coded/mapped in HCPCS listings)

Assay typeLC‑MS/MS quantitative measurement reported with risk score

Coding noteProprietary ceramide cardiology test mapping referenced (e.g., 0377U) in HCPCS mappings

82040	Albumin serum plasma or whole blood
82043	Albumin, urine (e.g., microalbumin) quantitative

82172	Apolipoprotein, each
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed
82310	Calcium, total
82397	Chemiluminescent assay (may be utilized for Leptin)
82533	Cortisol, total
82542	Column chromatography, includes mass spectrometry (e.g., LC/MS)
82565	Creatinine, blood
82607	Cyanocobalamin (Vitamin B-12)
82610	Cystatin C
82652	Vitamin D; 1,25 dihydroxy, includes fraction(s), if performed

83876	Myeloperoxidase (MPO) / HCPCS cross-referenced in document
0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative (example mapping shown)
0052U	Lipoprotein, high resolution fractionation and quantitation (example mapping)
0119U	Vertical auto profile ultracentrifugation lipoprotein classes/subclasses (example mapping)
0377U	Cardiology, ceramides by LC-MS/MS, plasma, quantitative report with risk score
0541U	Cardiovascular disease advanced NMR lipoprotein profile (Liposcale) with report

OpenPayer

Biomarker Testing in Risk Assessment and Management of Cardiovascular Disease

Coverage Criteria — Nontraditional Lipid and Cardiovascular Biomarker Testing

Coding — CPT, HCPCS and Test Mappings

Provider Actions — Authorization, Documentation, and Billing

Background — Biomarkers and Clinical Context

Definitions and Key Terms

Revision History